Key Takeaways
- NCCIH gap: NCCIH has no dedicated sea buckthorn herb page as of 2026. Americans searching for government-level guidance must rely on FDA, NIH ODS, and peer-reviewed clinical literature — all of which this guide compiles.
- FDA regulatory status: Sea buckthorn is regulated as a dietary supplement under DSHEA (1994). The FDA does not pre-approve dietary supplements before they reach the market. Manufacturers bear responsibility for safety.
- Toxicology verdict: In 90-day chronic toxicity studies, no adverse effects were observed at 10 mL/kg oil in rats. The NOAEL for aqueous extract is 100 mg/kg/day. Acute studies in mice showed no reactions at 20 mL/kg.
- Three drug interaction risks: Anticoagulants (warfarin, apixaban), antihypertensives, and diabetes medications all carry documented interaction potential — not theoretical. Physician clearance is non-negotiable for these groups.
- Bottom-line safety grade: "Possibly safe" at therapeutic supplement doses (1–3 g oil/day) for up to 90 days in healthy adults — using the same classification framework NCCIH applies to herbs it has reviewed.
The NCCIH Gap — Why No Official Page Exists
If you searched "NCCIH sea buckthorn" expecting to find an official NIH safety fact sheet, you found nothing — and that gap is itself medically significant. The National Center for Complementary and Integrative Health publishes detailed herb-specific safety pages for dozens of widely used supplements — ginkgo, St. John's wort, valerian, elderberry, turmeric — but sea buckthorn has not yet received a dedicated NCCIH review page as of May 2026.
This absence does not mean sea buckthorn is unsafe or unstudied. It means that NCCIH's editorial prioritization — driven by research volume, adverse event reports, and public query data — has not yet elevated sea buckthorn to the threshold required for a dedicated fact sheet. The research base is growing rapidly (over 40 human clinical trials indexed on PubMed as of 2025), and a formal NCCIH review is likely in the coming years.
In the meantime, Americans deserve a single, authoritative, government-aligned compilation of what US health bodies actually say about sea buckthorn safety. That is what this guide provides.
"The absence of an NCCIH page is not a safety signal. It is a research prioritization gap — one that this guide bridges with the existing clinical and toxicological evidence."
What NCCIH Is — and How It Reviews Herbal Supplements
Understanding why NCCIH's position matters requires understanding what NCCIH does. The National Center for Complementary and Integrative Health is one of 27 institutes and centers within the National Institutes of Health (NIH), operating under the US Department of Health and Human Services. It was established by Congress in 1991 as the Office of Alternative Medicine and received its current name in 2014[1].
NCCIH's mandate is to investigate complementary and integrative health practices — including herbal supplements — using rigorous scientific methods, and to communicate findings to the public. Its herb safety fact sheets are among the most trusted consumer resources in the USA because they synthesize clinical evidence and flag interactions in plain language, using a standardized safety classification framework.
How NCCIH classifies herb safety
When NCCIH does publish an herb fact sheet, it typically uses a safety classification framework aligned with natural medicines databases. The framework categories relevant to sea buckthorn, applied here using the available clinical evidence, are:
- Likely Safe — used at recommended doses with no clinically significant adverse effects in multiple human trials
- Possibly Safe — limited human safety data; appears safe at studied doses in short-term trials; insufficient long-term data
- Insufficient Evidence — not enough human data to determine safety profile for a specific form or population
- Possibly Unsafe — evidence of adverse effects or significant drug interactions exists
Applied to sea buckthorn: Based on available clinical evidence, sea buckthorn would most likely receive a "Possibly Safe" classification at 1–3 g oil/day for up to 90 days in healthy adults — and an "Insufficient Evidence" rating for pregnant women, long-term use beyond 90 days, and leaf/bark extracts — using NCCIH's standard framework.
FDA Regulatory Status of Sea Buckthorn
The FDA does not approve dietary supplements the way it approves pharmaceutical drugs. This is one of the most misunderstood facts in American supplement shopping. Understanding the FDA's actual relationship with sea buckthorn is essential for making informed safety decisions.
Sea buckthorn as food: GRAS status
Sea buckthorn berries consumed as a food — in jams, juices, teas, and other culinary applications — are considered Generally Recognized as Safe (GRAS) at ordinary consumption levels. This is the same baseline safety status as blueberries or cranberries[2]. The GRAS designation applies to the berry in its whole-food form, not to concentrated extracts or high-dose supplement formats.
Sea buckthorn as a dietary supplement: DSHEA framework
When sea buckthorn is sold as a capsule, oil supplement, or standardized extract in the USA, it falls under the Dietary Supplement Health and Education Act (DSHEA) of 1994. Under DSHEA, the FDA does not evaluate or approve dietary supplements before they reach store shelves[3]. The manufacturer is legally responsible for ensuring product safety before marketing.
Key practical implications for consumers:
- Sea buckthorn supplement labels cannot legally claim to "treat, cure, or diagnose" any disease — only structure/function claims ("supports skin health") are permitted
- All supplement labels must carry the disclaimer: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."
- GMP (Good Manufacturing Practices) regulations require proper manufacturing standards, but do not verify efficacy
- The FDA can take action against supplements found to be unsafe after they are on the market — but does not screen products before sale
How DSHEA Governs Supplement Safety in the USA
What the Dietary Supplement Health and Education Act means for sea buckthorn buyers
Pre-market approval: The FDA does NOT pre-approve sea buckthorn supplements before they are sold. A company can launch a sea buckthorn product without FDA review as long as the ingredient is not classified as a "new dietary ingredient" requiring a 75-day safety notification.
Manufacturer responsibility: The company selling the sea buckthorn product — not the FDA — is responsible for ensuring it is safe and accurately labeled before it reaches consumers. This creates significant quality variation across brands.
Post-market surveillance: The FDA monitors adverse events after products are on the market. As of May 2026, no FDA safety alert or recall has been issued for sea buckthorn. The FDA can remove products from the market if evidence of harm emerges.
What this means for you: Third-party testing (NSF International, USP, ConsumerLab) is the only way to verify that a sea buckthorn product actually contains what its label claims, at the stated dose, free of contaminants. The FDA doesn't do this for you — you must look for these certifications yourself.
Source: FDA.gov — Dietary Supplements[3]
Toxicology Data from NIH-Indexed Research
While NCCIH has not published a dedicated sea buckthorn fact sheet, the NIH's PubMed database indexes an extensive body of toxicological and safety research on Hippophae rhamnoides. This is the same evidence base NCCIH would draw on if it were to publish a fact sheet today. Here is what it shows.
Key safety findings from NIH-indexed studies
What the 90-day safety studies tell us
The most relevant toxicology reference for American consumers is the 90-day chronic safety study of aqueous sea buckthorn extract in rats at 100 mg/kg/day — the established NOAEL. At this dose, researchers observed no adverse effects on mean body weight, organ-to-body weight ratio, histological parameters, hematological markers, or biochemical parameters[4]. A parallel 90-day study of sea buckthorn oil at 10 mL/kg in rats found identical results — no toxicological signs, no fatalities[5].
One important caveat in the research: a separate 90-day study found that high doses of sea buckthorn extract (250–500 mg/kg in rats — far exceeding human equivalent therapeutic doses) caused a measurable increase in plasma glucose that returned to normal two weeks after stopping[6]. This is the scientific basis for the blood sugar interaction concern with diabetes medications — and it underscores why dose matters.
Dose matters critically: The glucose elevation seen in animal studies occurred at 250–500 mg/kg — doses 2.5 to 5× the NOAEL. At the human-equivalent therapeutic dose range (1–3 g of oil/day), no glucose abnormalities have been reported in clinical trials. However, the mechanism exists, which is why people on diabetes medications require medical supervision.
Genotoxicity and teratogenicity
Sea buckthorn has been specifically studied for genotoxic (DNA-damaging) and teratogenic (fetal-damaging) effects — two of the highest safety concerns for any herbal supplement. Current evidence shows no genotoxic activity in standard assays, and no maternal toxicity or embryotoxicity was observed in pregnant rats given sea buckthorn oil at doses up to 4.68 g/kg from gestation day 16[5]. These findings are reassuring, but human pregnancy studies remain absent — which is why therapeutic supplementation during pregnancy still requires OB/GYN clearance.
Safety Classification by Form and Use
Sea buckthorn is sold in multiple forms in the USA, and the safety profile varies by form. This table applies the same safety classification framework NCCIH uses for herbs it has formally reviewed.
| Form | Typical US Use | Duration Studied | Safety Classification | Notes |
|---|---|---|---|---|
| Berry (food) | Jams, juices, food ingredients | Traditional/ongoing | Likely Safe | GRAS at culinary amounts. Centuries of dietary use across Himalayan, Baltic, and Siberian populations. |
| Fruit/pulp oil (oral) | Anti-aging, cardiovascular support, dry eye | Up to 90 days (human) | Possibly Safe | No serious adverse events in clinical trials. GI side effects (loose stools) at higher doses. Drug interactions documented. |
| Seed oil (oral) | Inflammation, omega-3 supplementation | Up to 90 days (human) | Possibly Safe | Similar profile to fruit oil. Lower omega-7 content. Comparable safety record in trials. |
| Juice (oral) | Anti-aging, immune support, general nutrition | Up to 90 days (human) | Possibly Safe | GRAS as food beverage. High vitamin C may interact with certain medications at therapeutic doses. |
| Topical fruit oil | Skincare, eczema, anti-aging face use | Up to 13 days (cream, clinical); longer in cosmetic use | Possibly Safe | May cause redness or itching in sensitive individuals. Patch test before facial use. Orange staining cosmetic only. |
| Leaf extract (oral) | Antioxidant supplements, tea | Insufficient human data | Insufficient Data | Less studied than berry/oil. NIH-indexed research limited to in vitro and animal models. Human safety profile not established. |
| Bark/twig extract | Traditional medicine; rare in US market | Insufficient human data | Insufficient Data | Virtually no human clinical data. Avoid in therapeutic use until safety data exists. |
Drug Interactions — The Evidence-Based Full Table
This is the section most Americans searching "NCCIH sea buckthorn safety" are actually looking for: a clear, evidence-grounded table of what sea buckthorn can interfere with and why. These are not theoretical warnings — they are grounded in the documented pharmacological mechanisms of sea buckthorn's active compounds.
| Drug / Drug Class | Common US Brand Names | Interaction Risk | Mechanism | What to Do |
|---|---|---|---|---|
| Anticoagulants | Warfarin (Coumadin), apixaban (Eliquis), rivaroxaban (Xarelto) | High | Sea buckthorn contains vitamin E (tocopherols), omega-3 fatty acids, and flavonoids — all with documented antiplatelet activity that can compound anticoagulant effect and increase bleeding risk[7] | Do not use without prescriber clearance. Risk is serious — warfarin's therapeutic window is narrow. |
| Antiplatelet agents | Clopidogrel (Plavix), ticagrelor (Brilinta), aspirin (high-dose) | High | Same antiplatelet mechanism — additive effect raises bleeding risk | Consult prescriber. Particularly important before any surgical procedure. |
| Antihypertensives | Lisinopril, metoprolol, amlodipine, hydrochlorothiazide | Moderate | Sea buckthorn has modest blood-pressure-lowering effects. Combined with antihypertensives, additive hypotension may occur — particularly orthostatic hypotension[6] | Discuss with prescriber. Monitor blood pressure during first 4–6 weeks of combined use. |
| Diabetes medications | Metformin, insulin, glipizide, sitagliptin (Januvia), semaglutide (Ozempic) | Moderate | Omega-7 palmitoleic acid acts as a lipokine, modulating insulin sensitivity and glucose metabolism. May enhance hypoglycemic effect of diabetes drugs[6] | Monitor blood glucose. Consult endocrinologist before starting supplementation. |
| Immunosuppressants | Cyclosporine, tacrolimus (Prograf), mycophenolate | Moderate | Sea buckthorn's immune-modulating flavonoids (quercetin, isorhamnetin) may alter immune pathway activity relevant to transplant or autoimmune medication efficacy | Consult transplant team or rheumatologist. Not for use without specialist oversight. |
| Thyroid medications | Levothyroxine (Synthroid, Levoxyl) | Low | Berry fiber content may reduce levothyroxine absorption if taken simultaneously. Time-separation (2 hours between supplement and medication) mitigates risk. | Take sea buckthorn supplement at a different time of day from thyroid medication. |
| Chemotherapy agents | Varies by protocol | Consult Oncologist | Antioxidant compounds may theoretically interfere with oxidative-mechanism chemotherapy agents. This is a general supplement concern, not sea-buckthorn-specific. | Always inform oncologist of all supplement use during cancer treatment. |
How to use this table: These interaction categories cover an estimated 40% of American adults on at least one chronic prescription medication. If you fall into any of these categories, the standard protocol is: inform your prescriber, start at the lowest effective dose (0.5–1 g/day), and monitor for any change in how your medication is working for the first 4–6 weeks.
Safety by Population Group
The same safety classification NCCIH applies by population group — here applied to sea buckthorn using available clinical and toxicological evidence.
The core population in all clinical trials. 90-day studies consistently show no serious adverse events. GI side effects (loose stools) occur in a small minority and resolve with dose reduction. This is the "green light" group.
Drug interactions are pharmacologically documented for anticoagulants, antihypertensives, and diabetes drugs. Physician review is not optional — it is the appropriate safety protocol for this group.
Animal teratogenicity data is reassuring. No human pregnancy RCTs exist for therapeutic doses. Culinary use (berries in food) is considered safe. Therapeutic supplementation requires OB/GYN clearance. This is the standard NCCIH position for herbs without human pregnancy data.
No human data on sea buckthorn compound transfer into breast milk at therapeutic doses. Culinary consumption likely safe based on traditional use. Therapeutic supplementation not recommended without healthcare provider guidance.
One pediatric clinical study found sea buckthorn oral use was safe in children ages 1–7 for up to 8 weeks. Beyond this age range and duration, insufficient data exists. Therapeutic supplementation in children requires pediatric medical guidance.
Sea buckthorn's antiplatelet activity increases bleeding risk during and after surgical procedures. Standard medical guidance: stop all herbal supplements with antiplatelet activity at least 2 weeks before any elective surgery.
People with hemophilia, von Willebrand disease, or other bleeding disorders should avoid therapeutic sea buckthorn supplementation. The antiplatelet activity — even if mild in healthy adults — is contraindicated in this population.
Older adults are more likely to be on multiple prescription medications — polypharmacy significantly increases interaction risk. The supplement profile is otherwise favorable for older adults (dry eye, cardiovascular support, skin). Medication review is the key step.
Who Should Avoid Sea Buckthorn
Groups Requiring Physician Review Before Using Sea Buckthorn
- People on warfarin, apixaban, rivaroxaban, or clopidogrel. The antiplatelet interaction is pharmacologically real and the consequences of excessive anticoagulation — internal bleeding, stroke — are serious. This is not a theoretical risk.
- People scheduled for surgery within 2 weeks. All supplements with antiplatelet activity should be stopped at least 2 weeks before any elective surgical procedure. Inform your surgeon of all supplements you take.
- Anyone with a known bleeding disorder. Hemophilia, von Willebrand disease, idiopathic thrombocytopenic purpura, or any condition that impairs normal clotting requires medical clearance before any antiplatelet-active supplement.
- Pregnant women at therapeutic doses. Insufficient human pregnancy data means the precautionary principle applies. Culinary berry consumption is generally safe; concentrated supplementation is not.
- Organ transplant recipients on immunosuppressants. The flavonoid content of sea buckthorn may alter immune-modulating drug activity. Transplant safety is not a context for self-prescribed supplementation.
- Active cancer patients on chemotherapy. Inform your oncologist before starting any supplement, including sea buckthorn. Antioxidant supplements may interfere with oxidative chemotherapy mechanisms.
- People with berry or Elaeagnaceae family allergies. Cross-reactivity with related plants is possible. Patch test before topical use; consult an allergist before oral supplementation.
How to Buy Safe Sea Buckthorn in the USA: The DSHEA Consumer Checklist
Because the FDA does not pre-approve sea buckthorn supplements, the burden of quality verification falls entirely on the consumer. Here is what to look for — and what to avoid — when buying in the USA.
DSHEA Consumer Safety Checklist
Frequently Asked Questions
Does NCCIH have a sea buckthorn safety page?
As of May 2026, NCCIH does not have a dedicated sea buckthorn herb page. NCCIH publishes safety fact sheets for many common herbal supplements, but sea buckthorn has not yet been formally reviewed and published as a standalone NCCIH resource. Americans seeking government-level safety guidance on sea buckthorn must currently rely on FDA regulatory guidance, NIH Office of Dietary Supplements data, and peer-reviewed literature — all of which this guide synthesizes.
Is sea buckthorn FDA approved?
Sea buckthorn is not FDA-approved as a drug. Under the Dietary Supplement Health and Education Act (DSHEA) of 1994, it is regulated as a dietary supplement — a category of food. The FDA does not pre-approve dietary supplements before they reach the market. Sea buckthorn at culinary amounts is GRAS (Generally Recognized as Safe). Supplement manufacturers are responsible for ensuring product safety before selling[3].
Is sea buckthorn safe according to clinical research?
At 1–3 grams of oil per day for up to 90 days, sea buckthorn is considered "possibly safe" in healthy adults — using the same framework NCCIH applies to herbs it has formally reviewed. In 90-day chronic toxicity studies, no adverse effects were observed at the established NOAEL doses. Human clinical trials lasting up to 90 days have reported no serious adverse events[4].
What drug interactions does sea buckthorn have?
Sea buckthorn has three primary interaction categories: anticoagulants and antiplatelet agents (warfarin, apixaban, clopidogrel) due to mild antiplatelet activity; antihypertensive medications due to additive blood-pressure-lowering effects; and diabetes medications (insulin, metformin) due to omega-7's blood-glucose-lowering lipokine signaling[7]. These are mechanistically grounded, not theoretical.
What is the NOAEL for sea buckthorn?
The No Observed Adverse Effect Level (NOAEL) for sea buckthorn aqueous extract in rats is 100 mg/kg/day, established in a 90-day study. For sea buckthorn oil, the NOAEL is 10 mL/kg in a 90-day chronic rat study. Acute toxicity studies found no adverse reactions in mice given 20 mL/kg of sea buckthorn oil[5].
Is sea buckthorn safe during pregnancy?
Therapeutic sea buckthorn supplementation during pregnancy has insufficient human safety data. Animal teratogenicity studies are reassuring — no embryotoxicity was found at 4.68 g/kg in pregnant rats. However, the absence of human pregnancy trials means therapeutic supplementation should only be undertaken with OB/GYN clearance. Culinary berry consumption in food is generally considered safe[5].
How does sea buckthorn compare to other herbs NCCIH has reviewed for safety?
Based on available evidence, sea buckthorn's safety profile is comparable to herbs like elderberry, rosehip, and goji berry that NCCIH classifies as "possibly safe" at studied doses in healthy adults. It has a stronger safety evidence base than many popular herbs on the US market — but fewer long-term human trials than well-established herbs like ginkgo or valerian. The drug interaction risk profile is real and important — on par with herbs like ginger (antiplatelet) and St. John's wort (multiple interactions).
The Bottom Line: What US Authorities Say About Sea Buckthorn Safety
NCCIH doesn't yet have a sea buckthorn page. The FDA hasn't issued a safety alert. NIH ODS doesn't have a dedicated fact sheet. What exists is a substantial, growing body of peer-reviewed safety research — all indexed on PubMed, all publicly accessible — that paints a consistent picture: sea buckthorn is a well-tolerated supplement with a genuine safety profile for healthy adults at evidence-based doses.
The gaps in US authority guidance are not evidence of danger — they are evidence of a supplement that is growing in scientific prominence faster than government review processes can keep up with. Every indication is that when NCCIH does publish a sea buckthorn fact sheet, it will reflect the same clinical evidence this guide has compiled: a "possibly safe" rating for healthy adults, clear drug interaction warnings for three medication categories, and insufficient data for pregnancy, long-term use, and leaf extracts.
What this means practically: If you are a healthy adult with no chronic medications, sea buckthorn at 1–3 g/day is supported by the same quality of evidence that would earn it a favorable NCCIH safety rating. If you take prescription medications in the interaction categories above, physician review is not optional — it is the appropriate safety standard that any responsible US health authority, including NCCIH, would recommend.